Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice.
about
Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteinsAnthrax prophylaxis: recent advances and future directionsParticulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogensAnalysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assaysStable dry powder formulation for nasal delivery of anthrax vaccineRabies virus glycoprotein as a carrier for anthrax protective antigenAnthrax vaccination strategiesMicroneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine.Evaluation of combinatorial vaccines against anthrax and plague in a murine modelA single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challengeEfficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthraxAnthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine.New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens.Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen.Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategyMucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodiesColonic immune stimulation by targeted oral vaccine.A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge.Vaccines for Category A bioterrorism diseases.Immunological aspects of polymer microsphere vaccine delivery systems.Acetalated Dextran Microparticulate Vaccine Formulated via Coaxial Electrospray Preserves Toxin Neutralization and Enhances Murine Survival Following Inhalational Bacillus Anthracis Exposure.Bacillus anthracis, a story of nature subverted by man.An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimenPast, imminent and future human medical countermeasures for anthrax.Pulmonary vaccine delivery.Intranasal vaccines for protection against respiratory and systemic bacterial infections.Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism.Combinatorial evaluation of in vivo distribution of polyanhydride particle-based platforms for vaccine delivery.Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.Anthrax vaccines: present status and future prospects.Glycan surface antigens from Bacillus anthracis as vaccine targets: current status and future perspectives.Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice.Protection against inhalation anthrax by immunization with Salmonella enterica serovar Typhi Ty21a stably producing protective antigen of Bacillus anthracis.
P2860
Q24562788-64C35BE4-D659-42ED-9E35-B71D06D822BFQ26781366-D4D81666-4BC4-41C0-9EBE-33CA73A63E6CQ27011190-A8FAF7A5-EA46-43AE-9F69-CC65F1567807Q28383562-04F5843B-35E2-4231-93AD-4AF1CDDB3009Q28386405-6F24A5F6-DAF0-418E-8EF9-F9CB89C90CCBQ28391261-D0C8C8CE-4FEB-48DD-9626-B02B343DBDB2Q28392248-2BFDB46A-6ECB-48AC-BDD5-F101916402ACQ33259889-ECB868AB-11C4-4B0F-AF08-D3FCE05073D0Q33283821-D0549720-82A2-4DEA-B901-3AD9C825AC45Q33360151-F7E2F755-518D-4F9B-808A-A4416D9DE02BQ33396429-C8D418ED-B7C7-4E03-B802-CE97DF10731BQ33505445-56A3850B-31E3-4D5A-A15A-B6C1E172F162Q33508318-C64534AC-D33E-4C6D-BF1B-D0EBF3465237Q33883273-CCAE2DEF-1AAC-4D4B-88BE-7498785069EAQ34025527-ABE62755-2D2F-496F-801C-7863AF8C0270Q34121874-DA9662B2-F8DB-4CDF-B57C-09BF6CB094BAQ34576128-F01EB96B-DB86-4121-BB6F-56CE7EEB4BE0Q34700706-B194ACD0-602B-4902-8E3C-D00C4031B13BQ35040844-F866F385-8E5F-46FC-895D-0AFD211A671DQ35809248-305BAA07-CD4D-4255-A107-36BE37FA6110Q36122915-A10BB96A-1CDF-4235-BD22-5E318132B0F1Q36234189-ACA45812-AAE5-43E6-9464-4BF0E3417B36Q36504794-9E47FD38-DFB0-4F15-BD8B-FD878F9752D7Q36565152-E6FA432F-3399-4C73-A7C1-A72B75763098Q36780141-D33E1C90-EE33-4CB8-A0EB-6FDEFE5279CCQ36837156-92A5E2D7-E3B5-41C8-929D-7514A1F3122BQ36901955-27DDFE11-4631-4F89-88A5-D9A0A3773A98Q36957938-2DE41BE8-033B-4B08-9471-DB0E4A29129EQ37404847-AA1C5AFC-C309-4301-AF6A-8CF3B218E401Q38132268-5C91A52A-1F4F-4FC4-B8C6-CC15C023B98BQ38215454-4F408368-19C5-448D-BE30-4DFE1D631C61Q40336288-0738F06E-2375-4892-A4AB-740780E5641FQ47162390-DBEC4078-88D1-4C41-8187-9AC3E1BD3567
P2860
Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Mucosal or parenteral administ ...... nst anthrax infection in mice.
@ast
Mucosal or parenteral administ ...... nst anthrax infection in mice.
@en
type
label
Mucosal or parenteral administ ...... nst anthrax infection in mice.
@ast
Mucosal or parenteral administ ...... nst anthrax infection in mice.
@en
prefLabel
Mucosal or parenteral administ ...... nst anthrax infection in mice.
@ast
Mucosal or parenteral administ ...... nst anthrax infection in mice.
@en
P2093
P2860
P1476
Mucosal or parenteral administ ...... nst anthrax infection in mice.
@en
P2093
E Diane Williamson
Emma L Waters
H Oya Alpar
Helen C Flick-Smith
Jim E Eyles
Julie Miller
Les W J Baillie
Richard Hebdon
Richard J Beedham
Tony J Stagg
P2860
P304
P356
10.1128/IAI.70.4.2022-2028.2002
P407
P577
2002-04-01T00:00:00Z